Resolution of the Expert Council on the problem of early diagnosis of Alzheimer's disease

Alzheimer's disease (AD) is the most common neurodegenerative disease and the most common cause of dementia. In daily practice, AD is often diagnosed late, while the early stages of the disease are overlooked or mistaken for cerebrovascular pathology. However, the efficacy of existing and newly developed (disease-modifying) AD therapies is the greatest in the early stages of the disease. An accurate diagnosis of AD is possible when biological markers of the main pathological process (cerebral amyloidosis, tauopathy) are detected using positron emission tomography or neurochemical examination of cerebrospinal fluid, which are gradually being introduced into practice in Russia. The experts discussed the clinical aspects of the use of biological markers, obtained in the leading specialized centers of our country for the diagnosis and treatment of cognitive impairment (CI). First and foremost, biomarker testing is indicated in patients with mild CI and mild dementia possibly associated with AD, so that disease-modifying (pathogenetic) therapy can be initiated as early as possible upon on its availability (currently, drugs for anti-amyloid disease-modifying therapy are not registered in the Russian Federation). Patients with a non-classical (non-amnestic) or atypical AD phenotype are another group of patients in whom it is also advisable to analyze biomarkers for differential diagnostic purposes.

Authors

Institutions

Publication Details

Journal
Neurology neuropsychiatry Psychosomatics
Published
2024-10-20
DOI
https://doi.org/10.14412/2074-2711-2024-5-111-119
Citations
1
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Resolution of the Expert Council on the problem of early diagnosis of Alzheimer's disease

Н. В. Вахнина, E. А. Mkhitaryan, В. В. Захаров, С. Н. Иллариошкин et al.
1 citations
Neurology neuropsychiatry Psychosomatics
Dementia and Cognitive Impairment Research
0.39
article

Resolution of the Expert Council on the problem of early diagnosis of Alzheimer's disease

Н. В. Вахнина, E. А. Mkhitaryan, В. В. Захаров, С. Н. Иллариошкин, Е Е Васенина, В. А. Парфенов, А Н Боголепова, А. Yu. Emelin, Yu. A. Shpilyukova, О С Левин, Gavrilova Si, О. Н. Ткачева, O. V. Kosivtsova, G. P. Kostyuk
article en
1 citations

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disease and the most common cause of dementia. In daily practice, AD is often diagnosed late, while the early stages of the disease are overlooked or mistaken for cerebrovascular pathology. However, the efficacy of existing and newly developed (disease-modifying) AD therapies is the greatest in the early stages of the disease. An accurate diagnosis of AD is possible when biological markers of the main pathological process (cerebral amyloidosis, tauopathy) are detected using positron emission tomography or neurochemical examination of cerebrospinal fluid, which are gradually being introduced into practice in Russia. The experts discussed the clinical aspects of the use of biological markers, obtained in the leading specialized centers of our country for the diagnosis and treatment of cognitive impairment (CI). First and foremost, biomarker testing is indicated in patients with mild CI and mild dementia possibly associated with AD, so that disease-modifying (pathogenetic) therapy can be initiated as early as possible upon on its availability (currently, drugs for anti-amyloid disease-modifying therapy are not registered in the Russian Federation). Patients with a non-classical (non-amnestic) or atypical AD phenotype are another group of patients in whom it is also advisable to analyze biomarkers for differential diagnostic purposes.

Neurology neuropsychiatry PsychosomaticsVol. 16(5)
Mental Health Research Institute (AU), Sechenov University (RU), Lomonosov Moscow State University (RU), S. M. Kirov Military Medical Academy (RU), Federal Almazov North-West Medical Research Centre (RU), Pirogov Russian National Research Medical University (RU), Russian Medical Academy of Continuous Professional Education (RU), Ministry of Health of the Russian Federation (RU), Moscow State University (TJ), Research Center of Neurology (RU), Federal Medical-Biological Agency (RU)
Good health and well-being
Openalex Percentile: Top 34%
Dementia and Cognitive Impairment Research
0.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.